ethyl-3,4-dihydro-7-methyl-3-oxoquinoxaline-2-carboxylate | 111425-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl-3,4-dihydro-7-methyl-3-oxoquinoxaline-2-carboxylate
• 英文别名: ethyl 3,4-dihydro-7-methyl-3-oxoquinoxaline-2-carboxylate；ethyl 7-methyl-3-oxo-4H-quinoxaline-2-carboxylate
• CAS: 111425-81-1
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: FIGCVWVQHLQPQV-UHFFFAOYSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl-3,4-dihydro-7-methyl-3-oxoquinoxaline-2-carboxylate 以 溶剂黄146 为溶剂， 反应 1.0h， 以45%的产率得到ethyl 3,4-dihydro-7-methyl-6-nitro-3-oxoquinoxaline-2-carboxylate
  参考文献：
  名称：

  6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both

  摘要：

  本发明提供了6,7-不对称二取代喹喔啉羧酸化合物及其加合盐，以及制备它们的方法，这些化合物对兴奋性氨基酸受体，特别是AMPA受体具有拮抗作用。本发明的6,7-不对称二取代喹喔啉羧酸化合物及其加合盐由下式表示（1式），其中Q、R、R1和R2如规范中所述。

  公开号：

  US06348461B1
• 作为产物：
  描述：

  3,4-二氨基甲苯 、 酮基丙二酸二乙酯 以 乙醇 为溶剂， 反应 3.0h， 生成 ethyl 3,4-dihydro-6-methyl-3-oxoquinoxaline-2-carboxylate 、 ethyl-3,4-dihydro-7-methyl-3-oxoquinoxaline-2-carboxylate
  参考文献：
  名称：

  6-subtituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both

  摘要：

  该发明提供了具有对兴奋性氨基酸受体拮抗作用的化合物，特别是具有6-取代-7-杂喹啉羧酸衍生物及其盐作为有效成分的AMPA受体，以及两者的制备方法。这些化合物是由式(1)表示的6-取代-7-杂喹啉羧酸衍生物，其中A表示一个单键或亚甲基(CH2)，Y表示一个氮原子或═CH—，V表示一个单键或亚甲基(CH2)，T表示一个羟基、氨基、较低的烷氧羰基、羧基、醛基或类似物，Q表示一个卤原子、较低的烷基或较低的烷氧基，R1表示一个羟基、较低的烷氧基或类似物，以及它们的盐。

  公开号：

  US06632813B1

文献信息

• Uncatalyzed condensation between aryl-1,2-diamines and diethyl bromomalonate: a one-pot access to substituted ethyl 3-hydroxyquinoxaline-2-carboxylates
  作者：Pranab Haldar、Bishnupada Dutta、Joyram Guin、Jayanta K. Ray

  DOI：10.1016/j.tetlet.2007.06.065

  日期：2007.8

  A one-pot method for the synthesis of substituted ethyl 3-hydroxyquinoxaline-2-carboxylates under solvent and catalyst free conditions has been developed.

  开发了一种在无溶剂和无催化剂条件下合成取代的3-羟基喹喔啉-2-羧酸乙酯的一锅法。
• TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS
  申请人：Kawanishi Eiji

  公开号：US20110160206A1

  公开（公告）日：2011-06-30

  The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X 1 and X 2 is N, and the other of X 1 and X 2 is CH; A is *-CH═CH—, *-C(Alk)=CH—, *-CH 2 —CH 2 — or *-O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y 0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有优异的PDE10抑制活性的三取代嘧啶化合物。本发明涉及一种由以下式[I0]表示的三取代嘧啶化合物或其药学上可接受的盐，以及制备该化合物的方法，以及将所述化合物用作PDE10抑制剂的用途，以及包含所述化合物作为活性成分的药物组合物：其中：X1和X2中的任一者为N，另一者为CH；A为*-CH═CH—，*-C(Alk)=CH—，*-CH2—CH2—或*-O—CH2—（*是与R1形成键）；Alk为较低的烷基基团；环B为可选择地取代的含氮脂肪杂环基团；R1为可选择地取代的喹唑啉基或可选择地取代的喝啉基；Y0为单取代或双取代的氨基团，或其药学上可接受的盐。
• 6,7-ASYMMETRICALLY DISUBSTITUTED QUINOXALINECARBOXYLIC ACID DERI VATIVES, ADDITION SALTS THEREOF, AND PROCESSES FOR THE PREPARATION OF BOTH
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP1020453A1

  公开（公告）日：2000-07-19

  The present invention provides compounds with antagonism against excitatory amino acid receptors, in particular, AMPA receptor, having 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives and their addition salts as effective ingredients, and processes for preparing them, and relates to 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives represented by a general formula (1) [wherein, Q denotes a halogen atom, lower alkyl group which may be substituted with halogen atom, general formula (2)         Ar-P-     (2) (wherein Ar denotes a phenyl group or naphthyl group which may have one or more substituents, and P denotes a lower alkylene, lower alkenylene, lower alkynylene, oxygen or sulfur atom), or general formula (3);         L-A-     (3) R denotes a nitro group, trifluoromethyl group, amino group which may be substituted, or general formula (7), R1 denotes an aralkyl group, phenyl group, naphthyl group, 5- or 6-membered heterocycle and its condensed ring (these may have one or more substituents on aromatic ring or heterocycle), hydrogen atom, lower alkyl group which may be substituted with halogen atom or cycloalkyl group, and R2 denotes a hydroxyl group, lower alkoxy group or general formula (6) ], and their addition salts.

  本发明提供了以6，7-不对称二取代的喹喔啉羧酸衍生物及其加成盐为有效成分的对兴奋性氨基酸受体，特别是AMPA受体具有拮抗作用的化合物及其制备工艺，并涉及通式(1)表示的6，7-不对称二取代的喹喔啉羧酸衍生物 [其中，Q 表示卤素原子、可被卤素原子取代的低级烷基、通式 (2) Ar-P- (2) (其中 Ar 表示苯基或萘基，可带有一个或多个取代基，P 表示低级亚烷基、低级亚烯基、低级亚炔基、氧原子或硫原子）或通式（3）； L-A- (3) R 表示硝基、三氟甲基、可被取代的氨基或通式（7）、 R1 表示芳烷基、苯基、萘基、5 或 6 元杂环及其缩合环（可在芳香环或杂环上有一个或多个取代基）、氢原子、可被卤素原子取代的低级烷基或环烷基，R2 表示羟基、低级烷氧基或通式（6）。 ] 以及它们的加成盐。
• Synthesis of substituted 2-ethoxycarbonyl- and 2-carboxyquinoxalin-3-ones for evaluation of antimicrobial and anticancer activity
  作者：Paolo Sanna、Antonio Carta、Mario Loriga、Stefania Zanetti、Leonardo Sechi

  DOI：10.1016/s0014-827x(98)00044-5

  日期：1998.7

  A series of variously substituted quinoxalin-3-ones bearing an ethoxycarbonyl or carboxy group in the C-2 position has been prepared and their structures proved by H-1 NMR spectroscopy. The obtained compounds were investigated in vitro for antimicrobial and anticancer activities. Preliminary results showed a moderate activity against a few strains of bacteria but no significant anticancer and anti-HIV activity. (C) 1998 Elsevier Science S.A. All rights reserved.
• 6,7-ASYMMETRICALLY DISUBSTITUTED QUINOXALINECARBOXYLIC ACID DERIVATIVES, ADDITION SALTS THEREOF, AND PROCESSES FOR THE PREPARATION OF BOTH
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP1020453B1

  公开（公告）日：2004-05-19